Taking stock of the drug industry, from the lab to the medicine chest

September 23, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Millions of Americans want to quit smoking. Critics say drugmakers and the FDA are failing them Smoking cessation doesn't work for most people, but new drugs have been stymied by low profit potential and FDA skepticism By Nicholas Florko Opinion: 40 doesn't look good on Hatch-Waxman On the Hatch-Waxman Act's 40th anniversary, it's time to examine its legacy and what it actually gave us: the world's highest drug prices. By Tahir Amin and Timi Iwayemi STAT+ | A mysterious anti 'Big Pharma' bus is barnstorming swing states A dark money group with Republican ties, Americans for Pharma Reform, uses GOP talking points in calling for lower drug prices, increased competition. By Rachel Cohrs Zhang Scott Olson/Getty Images STAT+ | Wegovy is among drugs set to be targeted in the next round of Medicare price negotiations, researchers say Medicare is set to negotiate the prices of 15 more drugs. Medicines that will probably be on the list are used for conditions like diabetes and cancer. By John Wilkerson STAT+ | PhRMA scores a small win in legal challenge to Medicare's drug price negotiation An appeals court revived the challenge to Medicare's drug price negotiation program and sent it back to a lower court in Texas. By Rachel Cohrs Zhang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser